Tech Center 1600 • Art Units: 1646 1674
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18405772 | HIGH CONCENTRATION SOLUTION ANTIBODY FORMULATIONS COMPRISING ANTI-IL-23p19 ANTIBODIES | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | Non-Final OA | NOVARTIS AG |
| 15505056 | COMPOSITIONS FOR IMPROVING THE HEALTH RELATED QUALITY OF LIFE OF RHEUMATOID ARTHRITIS PATIENTS | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 19187615 | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS | Final Rejection | MOONLAKE IMMUNOTHERAPEUTICS AG |
| 18921679 | METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY | Non-Final OA | MOONLAKE IMMUNOTHERAPEUTICS AG |
| 19095314 | IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS | Non-Final OA | Synthekine, Inc. |
| 17679675 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME | Non-Final OA | Merck Patent GmbH |
| 17743864 | Treatment of Genital Psoriasis | Non-Final OA | Eli Lilly and Company |
| 16643377 | Methods for Treating TNFa-Related Diseases | Final Rejection | Celltrion Inc. |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 18674352 | METHODS FOR TREATING PLAQUE PSORIASIS | Non-Final OA | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 17188648 | VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18045597 | Methods of Treatment Using Anti-IL-17A/F Antibodies | Non-Final OA | UCB BIOPHARMA SRL |
| 17897946 | TREATMENTS FOR ATOPIC DERMATITIS | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17555997 | TREATMENT OF SKIN LESIONS AND PRURITUS IN PRURIGO NODULARIS PATIENTS | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17406847 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | Final Rejection | Bright Peak Therapeutics AG |
| 18045534 | METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION | Non-Final OA | Amgen K-A, Inc. |
| 17045363 | SYNTHETIC SIGNALING CONSTRUCTS AND ITS USE | Non-Final OA | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF |
| 16771948 | PEPTIDE IMMUNOGENS OF IL-31 AND FORMULATIONS THEREOF FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS | Final Rejection | UBI US Holdings, LLC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy